The experimental molecule 5-tetradecyloxy-2-furoic acid works by disrupting lipid production while activating specific genes that utilize fat as an energy source. In preclinical trials, treated mice experienced an energy expenditure increase of up to 18% without any changes in body temperature or physical movement. The animals shed body fat, retained their lean muscle, and exhibited better insulin sensitivity alongside reduced liver fat. Although animal models yielded promising metabolic improvements, the compound must still be evaluated for safety and effectiveness in human clinical trials.
Key points
Researchers are investigating TOFA as an alternative to GLP-1 medications that suppress a…: Researchers are investigating TOFA as an alternative to GLP-1 medications that suppress appetite and trigger lean muscle loss.
The compound successfully improved insulin sensitivity while decreasing both liver fat an…: The compound successfully improved insulin sensitivity while decreasing both liver fat and triglyceride levels in animal subjects.
Human clinical trials are still required because the compound has only been tested in ani…: Human clinical trials are still required because the compound has only been tested in animal models to date.
Sources checked by our analysis pipeline: 1
- Date:
- November 19, 2026
- Source:
- University of California - Berkeley
- Summary:
- Researchers at UC Berkeley have identified a compound that could transform weight-loss treatment by helping the body burn more energy instead of suppressing appetite like Ozempic and Wegovy. In mice, the compound boosted energy expenditure by up to 18%, improved blood sugar control, reduced liver fat, and promoted weight loss without significant muscle loss. Even more promising, combining it with existing GLP-1 medications produced greater benefits than either treatment alone.
- Share:
A new approach to weight loss could help the body burn more fat while preserving muscle, potentially overcoming one of the major drawbacks of existing obesity treatments. Researchers at the University of California, Berkeley, have identified a compound that increases the amount of energy the body uses rather than simply reducing how much food a person eats.
In experiments with mice, the compound improved blood sugar regulation, reduced harmful blood fats, and helped obese animals lose fat without a significant reduction in lean muscle mass. It also increased energy expenditure by…
Persistent regional outbreaks have stripped multiple nations of their measles-free designations, prompting renewed public health scrutiny regarding community protection levels. Despite the shift in national status, medical guidance confirms that standard two-dose regimens continue to offer lifelong defense for the general population. Additional immunization measures are strictly targeted at specific demographic cohorts and vulnerable individuals facing elevated exposure risks.
Researchers have observed substantial disease control in advanced pancreatic cancer patients by combining a targeted daily medication with standard chemotherapy. The therapy works by deactivating specific genetic mutations that fuel tumour development across multiple difficult-to-treat cancers. While regulatory clearance has already been granted in the US, clinicians stress that extended trials are still essential to determine long-term survival impacts.
British Medical Association members in Northern Ireland are demanding full pay restoration to counter years of earnings erosion and worsening staff burnout. The industrial action arrives amid strict budget constraints at Stormont that currently prevent the local health department from funding even basic recommended increases. With senior medical colleagues staging a separate walkout days later, regional health services face severe winter capacity pressures and prolonged patient delays.